Professor Mu-Sheng Zeng currently serves as Deputy Director and Vice President of Sun Yat-sen University Cancer Center. He also holds key academic and leadership positions including President of the International Association for Research on Epstein-Barr Virus and Associated Diseases, Chairman of Tumor Microenvironment Society under the Chinese Anti-Cancer Association, Director of the Guangdong Provincial Engineering Technology Research Center for Tumor Immunity and Vaccines, President of the 4th Council of the Guangdong Society for Cell Biology, and Chairman of the 2024 Gordon Research Conference on Nasopharyngeal Carcinoma. Recognized for his outstanding contributions, Professor Zeng has been awarded as The Yangtze River Scholar Distinguished Professor by Ministry of Education of China, a recipient of the "Hundred Outstanding Talents of South Guangdong" honor, and a Young and Middle-Aged Expert with Outstanding Contributions to National Health (9th session). His research has been supported by significant funding, including the National Science Foundation for Distinguished Young Scholars, two National Key Research and Development Programs, and several State Key Program of National Natural Science of China.

Professor Zeng has long been dedicated to research on the carcinogenisis of Epstein-Barr virus (EBV) and targeted intervention strategies. He made the first discovery of EBV-specific receptors for epithelial cell infection, as well as the universal receptor shared by B cells and epithelial cells. Buillding on these findings, he proposed a novel theory of "multi-receptor sequential and synergistic mediation in EBV transcellular infection". He also established innovative EBV vaccine system and developed multiple candidate vaccines that have been successfully licensed to leading domestic enterprises.

He has published over 100 papers as a corresponding or co-corresponding author in leading international journals, including Nature, Nature Microbiology (2 papers), Cell Host & Microbe, Cancer Cell, Lancet Digital Health, Journal of Clinical Investigation, Nature Communication and PNAS. As the first principal investigator, he has been awarded the Second Prize of the National Natural Science Award (2023), the Higher Education Outstanding Scientific Research Output Awards (2022), the Guangdong Provincial Natural Science Award (2018 and 2023), and the First Prize of the Science and Technology Award of the Chinese Anti-Cancer Association (2019). He was recognized as an Elsevier Highly Cited Researcher, with an H-index of 70.

Science and Technology Awards

1. 2023 National Natural Science Award (Second Class), China   Project: Molecular Mechanisms of EBV Carcinogenesis and Targeted Interventions   Recipients: Musheng Zeng, Quentin Qiang Liu, Jin-Xin Bei, Miao Xu, Fan Bai

2. 2023 Guangdong Provincial Natural Science Award (First Class)   Project: Identification of High-Risk EBV Subtypes, Carcinogenic Mechanisms, and Targeted Interventions   Recipients: Musheng Zeng, Miao Xu, Fan Bai, Lin Feng, Hua Zhang, Tong Xiang, Qian Zhong, Yan Li, Liang-Tian Xia

3. 2022 Higher Education Outstanding Scientific Research Output Awards (First Class), China   Project: Identification, Infection, and Carcinogenic Mechanisms of High-Risk EBV Subtypes in Nasopharyngeal Carcinoma   Recipients: Musheng Zeng, Miao Xu, Lin Feng, Hua Zhang, Yi-Xin Zeng, Tong Xiang, Qian Zhong

4. 2018 Guangdong Provincial Natural Science Award (First Class)   Project: Etiology, Pathogenesis, and Molecular Biomarkers of EBV-Associated Nasopharyngeal Carcinoma   Recipients: Musheng Zeng, Yi-Xin Zeng, Libing Song, Dan Xie, Haiqiang Mai, Chao-Nan Qian, Sumei Cao, Wenqiong Xue

5. 2019 China Anti-Cancer Association Science and Technology Award (First Class)   Project: EBV Infection, Carcinogenic Mechanisms, and Molecular Biomarkers   Recipients: Musheng Zeng, Libing Song, Dan Xie, Haiqiang Mai, Yi-Xin Zeng, Chao-Nan Qian, Sumei Cao, Wenqiong Xue

Epstein-Barr virus (EBV) was the first human oncogenic virus to be discovered. It is assiciated with over 250,000 newly diagnosed cancer cases annually. EBV is strongly implicated in the pathogenesis of nasopharyngeal carcinoma, certain types of lymphomas, and gastric cancer. It is also the causative agent of infectious mononucleosis and systemic lupus erythematosus, thereby posing a major and multifaceted public health challenge. Despite its widespread impact, no vaccines or specific antiviral drugs have been approved for EBV.

Professor Zeng has long been committed to research on the mechanisms of EBV infection and pathogenesis. In response to the long-standing challenges of unclear mechanisms underlying EBV infection and pathogenesis, as well as the lack of effective prevention and control measures, he has conducted a series of studies. He identified key receptors for EBV infection, revealed the molecular mechanisms of EBV-induced oncogenesis and developed novel EBV candidate vaccines that have been successfully licensed to leading domestic vaccine enterprises. He has made systematic and innovative contributions to research on EBV virology and pathogenesis, establishing himself as a key leader in the field.  Key milestones include:

1. Identifying Key Receptors for EBV Infection and Proposing a Novel Theory of Multi-Receptor Cooperative Infection

Faced with the challenge of extremely low EBV infection efficiency in epithelial cells in vitro, Professor Zeng pioneered the development of an immortalized epithelial model that enhances EBV infection efficiency by nearly 40-fold. He identified key receptors mediating EBV infection in epithelial cells for the first time, including NMHC-ⅡA, NRP1, EphA2 and DSC2. Based on these findings, he revealed the sequential and synergistic mechanism underlying EBV infection, filling the research gap in mechanisms of EBV infection in epithelial cells, and providing innovative theoretical support and new targets for the development of viral entry inhibitors and anti-infection vaccines.

For a long time, it has been widely believed that EBV infects epithelial cells and B cells through distinct and cell-type-specific receptors, with no shared target for blocking infection. Using the aforementioned innovative infection model, he identified R9AP as a universal receptor that mediates EBV infection in both epithelial cells and B lymphocytes. This discovery solves the long-standing mystery of how EBV cross-infects these two types of target cells and proposes a systematic theoretical framework for EBV infection, in which the universal receptor R9AP serves as a central mediator and synergizes with cell-specific receptors to achieve infection.

The identification of these key receptors has filled the international research gap in the field of EBV entry receptors, propelling the field of EBV prevention and control into a new era characterized by well-defined mechanisms and clearly identified targets. These findings have been included in Fields Virology(7th edition), the premier virology textbook, and have been highlighted in reviews in leading journals such as Cell.

2. Discovering Key Events in EBV-Induced Nasopharyngeal Infection and Carcinogenesis

Professor Zeng led a large-scale prospective cohort study and found that a decrease in the level of the EBV glycoprotein antibody gp42-IgG is associated with an increased risk of NPC. Building on this research, gp42-IgG has been identified as the first protective antibody associated with nasopharyngeal mucosal carcinogenesis, serving as a key biomarker for early screening in high-risk populations. He also discovered, for the first time, that epithelial cells within premalignant nasopharyngeal mucosal lesions aberrantly express HLA-II, a viral receptor for B lymphocyte infection, thus breaking through the restriction on EBV cross-infection between epithelial cells and B lymphocytes.

These studies identified, for the first time, the protective antibody in nasopharyngeal mucosa, and clarified the critical time points and molecular events involved in EBV-induced carcinogenesis, laying an innovative theoretical foundation for the design of a new generation of anti-carcinogenic vaccines targeting gp42. Based on these findings, Professor Zeng was invited to author an expert perspective on the utility of gp42-IgG as a biomarker for high-risk nasopharyngeal carcinoma populations and the therapeutic potential of targeting gp42 for disease prevention and treatment.

3. Developing vaccines for the prevention of EBV infection and carcinogenesis

Building on the innovative discoveries of key receptors and infection mechanisms mentioned above, Professor Zeng further resolved the high-resolution structure of the EBV capsid, clarified the mechanism of virus-receptors interactions, and identified multiple highly potent neutralizing antibodies that block these interactions by targeting the EBV glycoproteins. Subsequently, he established an innovative self-assembling nanoparticle vaccine platform and developed novel candidate vaccines based on gHgL and gB, which can simultaneously provide protection against infection in both B cells and epithelial cells. The related achievements have been licensed to a leading vaccine enterprise, with preclinical process development and pharmacodynamic studies currently underway.

In response to the infection mechanisms of nasopharyngeal mucosal precancerous lesions, Professor Zeng developed a preventive cancer vaccine targeting gp42, aiming to prevent EBV infection at the premalignant mucosal stage. Meanwhile, he developed a therapeutic candidate vaccine targeting EBV antigens for the threatment of virus-associated tumors. In collaboration with innovative vaccine enterprises, he has completed preclinical pharmacodynamic studies, toxicological evaluations, and product quality testing. An application for clinical trial authorization (IND) is currently under submission.

Professor Zeng's work has provided a theoretical basis and implementation strategies for blocking EBV infection at its source and preventing virus-associated tumorigenesis. His research has also guided the development of a systematic portfolio of novel EBV vaccines. These achievements represent a significant breakthrough by Chinese scientific research in addressing major human infectious diseases, underscoring the global relevance and impact of China’s contributions to public health and translational virology.

1988   College Degree in Clinical Medicine

Jiangxi Medical College in Fuzhou, Jiangxi, China

1994  M.M. in Oncology

Sun Yat-Sen University, Guangzhou, China

1998  Ph.D. in Microbiology

Sun Yat-Sen University, Guangzhou, China

1999-2000  Postdoc in Biology

Tennessee State University, USA

2000-2003  Postdoc in Radiation Oncology

New England Medical Center, Tufts University, USA

Representive publications:

1. R9AP is a common receptor for EBV infection in epithelial cells and B cells. Yan Li ^#, Hua Zhang ^#, Cong Sun ^#, Xiao-Dong Dong ^#, Chu Xie, Yuan-Tao Liu, Ruo-Bin Lin, Xiang-Wei Kong, Zhu-Long Hu, Xiao-Yan Ma, Dan-Ling Dai, Qian-Ying Zhu, Yu-Chun Li, Ying Li, Shang-Xin Liu, Li Yuan, Peng-Hui Zhou, Song Gao, Ya-Ping Tang, Jin-Ying Yang, Ping Han, Andrew T McGuire, Bo Zhao, Jin-Xin Bei, Erle Robertson, Yi-Xin Zeng, Qian Zhong*, Mu-Sheng Zeng*. Nature. 2025 Aug;644(8075):205-213. doi: 10.1038/s41586-025-09166-w. Epub 2025 Jun 18.

2. Desmocollin 2 is a dominant entry receptor for Epstein-Barr virus infection of epithelial cells. Hua Zhang ^#, Yu-Chun Li ^#, De Pang #, Chu Xie ^#, Ting Zhang, Ying Li, Yan Li, Zi-Ying Jiang, Guo-Long Bu, Meng-Meng Liu, Ying-Rou Chen, Han-Xiao Fei, Ruo-Bin Lin, Pei-Huang Wu, Wen-Ting Du, Ge-Xin Zhao, Yi-Ling Luo, Ping Han, Qian Zhong*, Cong Sun*, Mu-Sheng Zeng*. Nat Microbiol. 2025 Jul 25. doi: 10.1038/s41564-025-02067-8.

3. A large-scale population-based study reveals that gp42-IgG antibody is protective against Epstein-Barr virus-associated nasopharyngeal carcinoma. Xiang-Wei Kong^#, Guo-Long Bu^#, Hua Chen^#, Yu-Hua Huang^#, Zhiwei Liu, Yin-Feng Kang, Yan-Cheng Li, Xia Yu, Biao-Hua Wu, Zi-Qian Li, Xin-Chun Chen, Shang-Hang Xie, Dong-Feng Lin, Tong Li, Shu-Mei Yan, Run-Kun Han, Nan Huang, Qian-Yu Wang, Yan Li, Ao Zhang, Qian Zhong, Xiao-Ming Huang, Weimin Ye, Ming-Fang Ji*, Yong-Lin Cai*, Su-Mei Cao*, Mu-Sheng Zeng*. J Clin Invest. 2024 Nov 26:e180216. doi: 10.1172/JCI180216.

4. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cong Sun^#, Yin-Feng Kang^#, Xin-Yan Fang^#, Yi-Na Liu^#, Guo-Long Bu, Ao-Jie Wang, Yan Li, Qian-Ying Zhu, Hua Zhang, Chu Xie, Xiang-Wei Kong, Yong-Jian Peng, Wen-Jie Lin, Ling Zhou, Xin-Chun Chen, Zheng-Zhou Lu, Hui-Qin Xu, Dong-Chun Hong, Xiao Zhang, Ling Zhong, Guo-Kai Feng, Yi-Xin Zeng, Miao Xu, Qian Zhong*, Zheng Liu*, Mu-Sheng Zeng*. Cell Host Microbe. 2023 Nov 8;31(11):1882-1897.e10. doi: 10.1016/j.chom.2023.09.011.

5. Neuropilin 1 is an entry receptor for KSHV infection of mesenchymal stem cell through TGFBR1/2-mediated macropinocytosis. Zheng-Zhou Lu^#, Cong Sun^#, Xiaolin Zhang, Yingying Peng, Yan Wang, Yan Zeng, Nannan Zhu, Yan Yuan*, Mu-Sheng Zeng*. Sci Adv. 2023 May 24;9(21):eadg1778. doi: 10.1126/sciadv.adg1778. Epub 2023 May 24.

6. Single-cell transcriptomic analysis defines the interplay between tumor cells,viral infection, and the microenvironment in nasopharyngeal carcinoma.Shanzhao Jin^#, Ruoyan Li^#, Ming-Yuan Chen^#, Chao Yu^#, Lin-Quan Tang^#, Yan-Min Liu, Jiang-Ping Li, Yi-Na Liu, Yi-Ling Luo, Yifan Zhao, Yu Zhang, Tian-Liang Xia, Shang-Xin Liu, Qi Liu, Guan-Nan Wang, Rui You, Jing-Yun Peng, Jiang Li, Feng Han, Jianwei Wang, Qiu-Yan Chen, Li Zhang, Hai-Qiang Mai, Benjamin E Gewurz, Bo Zhao, Lawrence S Young, Qian Zhong*, Fan Bai*, Mu-Sheng Zeng*. Cell Res. 2020 Nov;30(11):950-965. doi: 10.1038/s41422-020-00402-8. Epub 2020 Sep 8.

7. Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Hua Zhang^#, Yan Li^#, Hong-Bo Wang^#, Ao Zhang, Mei-Ling Chen, Zhi-Xin Fang, Xiao-Dong Dong, Shi-Bing Li, Yong Du, Dan Xiong, Jiang-Yi He, Man-Zhi Li, Yan-Min Liu, Ai-Jun Zhou, Qian Zhong, Yi-Xin Zeng, Elliott Kieff, Zhiqiang Zhang, Benjamin E. Gewurz, Bo Zhao* & Mu-Sheng Zeng*. Nat Microbiol. 2018 Feb;3(2):1-8. doi: 10.1038/s41564-017-0080-8. Epub 2018 Jan 1.

8. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Hong-Bo Wang^#, Hua Zhang^#, Jing-Ping Zhang, Yan Li, Bo Zhao, Guo-Kai Feng, Yong Du, Dan Xiong, Qian Zhong, Wan-Li Liu, Huamao Du, Man-Zhi Li, Wen-Lin Huang, Sai Wah Tsao, Lindsey Hutt-Fletcher, Yi-Xin Zeng, Elliott Kieff, Mu-Sheng Zeng*. Nat Commun. 2015 Feb 11:6:6240. doi: 10.1038/ncomms7240.

9. Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Dan Xiong^#, Yong Du^#, Hong-Bo Wang^#, Bo Zhao, Hua Zhang, Yan Li, Li-Juan Hu, Jing-Yan Cao, Qian Zhong, Wan-Li Liu, Man-Zhi Li, Xiao-Feng Zhu, Sai Wah Tsao, Lindsey M Hutt-Fletcher, Erwei Song, Yi-Xin Zeng, Elliott Kieff*, Mu-Sheng Zeng*.  Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11036-41. doi: 10.1073/pnas.1513359112. Epub 2015 Aug 19.

10. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. Li-Bing Song^#, Jun Li^#, Wen-Ting Liao^#, Yan Feng, Chun-Ping Yu, Li-Juan Hu, Qing-Li Kong, Li-Hua Xu, Xing Zhang, Wan-Li Liu, Man-Zhi Li, Ling Zhang, Tie-Bang Kang, Li-Wu Fu, Wen-Lin Huang, Yun-Fei Xia, Sai Wah Tsao, Mengfeng Li, Vimla Band, Hamid Band, Qing-Hua Shi, Yi-Xin Zeng, Mu-Sheng Zeng*. J Clin Invest. 2009 Dec;119(12):3626-36. doi: 10.1172/JCI39374. Epub 2009 Nov 2.

Other publications:

1. The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma. Ting Yang^#, Zhi-Rui Lin^#, Tian-Liang Xia^#, Shang-Xin Liu^#, Bo-Yu Yuan, Yi-Ling Luo, Wen-Ting Du, Chao-Bo Lei, Yong-Zhan Nie, Mu-Sheng Zeng*, Qian Zhong*. Cell Death Differ. Published online July 5, 2025. doi:10.1038/s41418-025-01536-1.

2. Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors. Zhi-Rui Lin^#, Tian-Liang Xia^#, Meng-Yao Wang^#, Lan-Jun Zhang, Yan-Min Liu, Bo-Yu Yuan, Ai-Jun Zhou, Li Yuan, Jian Zheng, Jin-Xin Bei, Dong-Xin Lin, Mu-Sheng Zeng*, Qian Zhong*. Med. 2025;6(5):100568. doi:10.1016/j.medj.2024.12.002.

3. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Shang-Xin Liu^#,  Tao-Wei Wu^#, Dong-Hua Luo, Le-Le Zhang, Lu Zhou, Yi-Ling Luo, Wen-Ting Du, Ting-Ting Huang, Sizun Jiang, Zhe Zhang*, Ping Han*, Mu-Sheng Zeng*, Qian Zhong*. Cell Rep Med. 2025;6(7):102200. doi:10.1016/j.xcrm.2025.102200.

4. OASL enhances mRNA translation and reprograms lipid metabolism to promote cancer progression. Shi-Bing Li^#, Li Yuan^#, Qian-Ying Zhu^#, Gong Zhang, Yuan-Tao Liu,  Ming-Hui Gao, Fei Han, Zhi-Rui Lin, Hua Zhang, Lin-Quan Tang, Li Sun, Qing-Yu He, Er-Wei Song, Lawrence S Young, Yu-Chun Li, Hai-Qiang Mai, Mu-Sheng Zeng*, Qian Zhong*. Cell Rep. 2025;44(7):115901. doi:10.1016/j.celrep.2025.115901.

5. Targeting EBV gp42 for nasopharyngeal carcinoma prevention. Cong Sun^#, Le-Le Zhang, Mu-Sheng Zeng*. Mol Ther. 2025;33(7):2987-2989. doi:10.1016/j.ymthe.2025.06.005.

6. mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust AntiTumor Immunityin Mice. Ge-Xin Zhao, Guo-Long Bu, Gang-Feng Liu, Xiang-Wei Kong, Cong Sun, Zi-Qian Li, Dan-Ling Dai, Hai-Xia Sun, Yin-Feng Kang, Guo-Kai Feng*, Qian Zhong*, Mu-Sheng Zeng*. Adv Sci (Weinh). 2023 Dec;10(35):e2302116. doi: 10.1002/advs.202302116. Epub 2023 Oct 27.

7. Highly sensitive detection platform-based diagnosis of oesophageal squamous cell carcinoma in China: a multicentre, case-control, diagnostic study. Yu Wang^#, Shan Xing^#, Yi-Wei Xu^#, Qing-Xia Xu^#, Ming-Fang Ji^#, Yu-Hui Peng^#, Ya-Xian Wu, Meng Wu, Ning Xue, Biao Zhang, Shang-Hang Xie, Rui-Dan Zhu, Xin-Yuan Ou, Qi Huang, Bo-Yu Tian, Hui-Lan Li, Yu Jiang, Xiao-Bin Yao, Jian-Pei Li, Li Ling, Su-Mei Cao*, Qian Zhong*, Wan-Li Liu*, Mu-Sheng Zeng*. Lancet Digit Health. 2024 Oct;6(10):e705-e717. doi: 10.1016/S2589-7500(24)00153-5.

8. Research landmarks on the 60th anniversary of Epstein-Barr virus. Lan-Yi Zhong^#, Chu Xie^#, Le-Le Zhang^#, Yan-Lin Yang^#, Yuan-Tao Liu^# Ge-Xin Zhao, Guo-Long Bu, Xian-Shu Tian, Zi-Ying Jiang Bo-Yu Yuan, Peng-Lin Li, Pei-Huang Wu, Wei-Hua Jia, Christian Münz, Benjamin E Gewurz, Qian Zhong, Cong Sun, Mu-Sheng Zeng*. Sci China Life Sci. 2025;68(2):354-380. doi:10.1007/s11427-024-2766-0.

9. Structural basis of Epstein-Barr virus gp350 receptor recognition and neutralization. Cong Sun^#, Xin-Yan Fang, Guo-Long Bu, Lan-Yi Zhong, Chu Xie, Ge-Xin Zhao, Sen-Fang Sui, Zheng Liu, Mu-Sheng Zeng*. Cell Rep. 2025;44(1):115168. doi:10.1016/j.celrep.2024.115168.

10. AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation. Dan-Ling Dai^#, Chu Xie^#, Lan-Yi Zhong^#, Shang-Xin Liu, Le-Le Zhang, Hua Zhang, Xing-Ping Wu, Zhou-Ming Wu, Kexin Kang, Yan Li, Ya-Meng Sun, Tian-Liang Xia, Chen-Song Zhang, Ao Zhang, Ming Shi, Cong Sun, Mei-Ling Chen, Ge-Xin Zhao, Guo-Long Bu, Yuan-Tao Liu, Kui-Yuan Huang, Zheng Zhao, Shu-Xin Li, Xiao-Yong Zhang, Yun-Fei Yuan, Shi-Jun Wen, Lingqiang Zhang, Bin-Kui Li*, Qian Zhong*, Mu-Sheng Zeng*. Signal Transduct Target Ther. 2024 Oct 9;9(1):281. doi: 10.1038/s41392-024-01978-y.

11. Research landmarks on the 60th anniversary of Epstein-Barr virus. Lan-Yi Zhong^#, Chu Xie^#, Le-Le Zhang^#, Yan-Lin Yang^#, Yuan-Tao Liu^#, Ge-Xin Zhao, Guo-Long Bu, Xian-Shu Tian, Zi-Ying Jiang, Bo-Yu Yuan, Peng-Lin Li, Pei-Huang Wu, Wei-Hua Jia, Christian Münz, Benjamin E Gewurz, Qian Zhong, Cong Sun*, Mu-Sheng Zeng*. Sci China Life Sci. 2024 Nov 4. doi: 10.1007/s11427-024-2766-0. Online ahead of print.

12. Prophylactic vaccines against Epstein-Barr virus. Ling Zhong, Qinjian Zhao, Mu-Sheng Zeng, Xiao Zhang*. Lancet. 2024 Aug 31;404(10455):845. doi: 10.1016/S0140-6736(24)01608-8.

13. Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression. Xudong Wan, Yuantao Liu, Yiman Peng, Jian Wang, Shu-mei Yan, Lu Zhang, Wanchun Wu, Lei Zhao, Xuelan Chen, Kexin Ren, Haicheng Long, Yiling Luo, Qin Yan, Lele Zhang, Dengzhi Lei, Pengpeng Liu, Shujun Li, Lihui Liu, Linjie Guo, Jiajia Du, Mengsha Zhang, Siqi Dai, Yi Yang, Hongyu Liu, Nianyong Chen, Jinxin Bei, Lin Feng, Yu Liu*, Mu-sheng Zeng*, Chong Chen*, and Qian Zhong*. Adv Sci (Weinh). 2024 Sep;11(36):e2403161. doi: 10.1002/advs.202403161. Epub 2024 Jul 25.

14. A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Jie Yang^#, Qiao-Li Wang^#, Guan-Nan Wang, Jia-Cong Ye, Zi-Qian Li, Jing-Yun Wang, Zhao-Hui Liang, Shu-Xin Li, Cong Sun, Wen-Ting Liao, Yi-Jun Gao, Jing Wang, Yong Mao, Chunjing Yu, Guo-Kai Feng*, Mu-Sheng Zeng*. Cell Discov. 2024 Jun 28;10(1):70. doi: 10.1038/s41421-024-00699-4.

15. Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection. Ge-Xin Zhao^#, Xin-Yan Fang^#, Guo-Long Bu^#, Shuai-Jia-Bin Chen, Cong Sun, Ting Li, Chu Xie, Yu Wang, Shu-Xin Li, Ning Meng, Guo-Kai Feng, Qian Zhong, Xiang-Wei Kong*, Zheng Liu*, Mu-Sheng Zeng*. Cell Rep Med. 2024 May 21;5(5):101573. doi: 10.1016/j.xcrm.2024.101573.

16. Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases. Hui-Lan Li^#, Lan-Yi Zhong^#, Yin-Feng Kang, Yan-Lan Yang, Liang Shi, Ai-Xia Zhai, Chao Wu, Mu-Sheng Zeng*, Qian-Ying Zhu*. J Med Virol. 2024 Apr;96(4):e29595. doi: 10.1002/jmv.29595.

17. Navigating Epstein-Barr virus autoimmunity: role of NK cells and T cells in multiple sclerosis. Chu Xie, Cong Sun*, Mu-Sheng Zeng*. Signal Transduct Target Ther. 2024 Feb 29;9(1):48. doi: 10.1038/s41392-024-01774-8.

18. Enhancing immune defense against COVID-19: Alveolar delivery of mucosal vaccines. Pei-Huang Wu^#, Dong-Chun Hong^#, Chu Xie, Mu-Sheng Zeng*, Cong Sun*. Sci Bull (Beijing). 2024 Dec 15;69(23):3637-3639. doi: 10.1016/j.scib.2024.07.032. Epub 2024 Jul 19.

19. Elucidation of the neutralizing antibody evasion of emergent SARS-CoV-2 Omicron sub-lineages using structural analysis. Cong Sun^#, Yuan-Tao Liu^#, Yin-Feng Kang, Chu Xie, Shu-Xin Li, Yu-Tong Lu, Mu-Sheng Zeng*. Sci China Life Sci. 2023 Dec;66(12):2935-2938. doi: 10.1007/s11427-023-2393-3. Epub 2023 Sep 1.

20. Anti-EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy. Chu Xie, Lan-Yi Zhong, Guo-Long Bu, Ge-Xin Zhao, Bo-Yu Yuan, Yuan-Tao Liu, Cong Sun*, Mu-Sheng Zeng*. J Med Virol. 2023 May;95(5):e28793. doi: 10.1002/jmv.28793.

21. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Cong Sun, Chu Xie, Guo-Long Bu, Lan-Yi Zhong & Mu-Sheng Zeng*. Signal Transduct Target Ther. 2022 Jun 28;7(1):202. doi: 10.1038/s41392-022-01039-2.

22. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Yin-Feng Kang^#, Cong Sun^#, Jing Sun ^#, Chu Xie, Zhen Zhuang, Hui-Qin Xu, Zheng Liu, Yi-Hao Liu, Sui Peng, Run-Yu Yuan*, Jin-Cun Zhao*, Mu-Sheng Zeng*. Nat Commun. 2022 May 13;13(1):2674. doi: 10.1038/s41467-022-30222-w.

23. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. Cong Sun^#, Run-Yu Yuan^#, Chu Xie^#, Jiu-Feng Sun, Xin-Yan Fang, Yi-Sha Hu, Xiao-Hui Yu, Zheng Liu, Mu-Sheng Zeng*, Yin-Feng Kang*. J Virol. 2022 Jul 13;96(13):e0038322. doi: 10.1128/jvi.00383-22. Epub 2022 Jun 14.

24. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses. Xiang-Wei Kong^#, Xiao Zhang^#, Guo-Long Bu^#, Hui-Qin Xu, Yin-Feng Kang, Cong Sun, Qian-Ying Zhu, Run-Bo Ma, Zheng Liu, Yi-Xin Zeng, Mu-Sheng Zeng*, Zhu-Long Hu*. J Virol. 2022 May 11;96(9):e0033622. doi: 10.1128/jvi.00336-22. Epub 2022 Apr 11.

25. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Cong Sun ^#, Yin-Feng Kang ^#, Yuan-Tao Liu, Xiang-Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yi-Hao Liu, Sui Peng, Guo-Kai Feng*, Zheng Liu*, Mu-Sheng Zeng*. Signal Transduct Target Ther. 2022 Feb 8;7(1):42. doi: 10.1038/s41392-022-00910-6.

26. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development. Cong Sun, Xin-Chun Chen, Yin-Feng Kang, Mu-Sheng Zeng*. Front Immunol. 2021 Jun 8:12:677027. doi: 10.3389/fimmu.2021.677027.  eCollection 2021.

27. PD-1+CXCR5-CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. Jiang-Ping Li, Chang-You Wu, Ming-Yuan Chen, Shang-Xin Liu, Shu-Mei Yan, Yin-Feng Kang, Cong Sun, Jennifer R Grandis, Mu-Sheng Zeng*, Qian Zhong*. J Immunother Cancer. 2021 Jul;9(7):e002101. doi: 10.1136/jitc-2020-002101 .

28. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Qian-Ying Zhu ^#, Sisi Shan ^#, Jinfang Yu ^#, Si-Ying Peng, Cong Sun, Yanan Zuo, Lan-Yi Zhong, Shu-Mei Yan, Xiao Zhang, Ziqing Yang, Yong-Jian Peng, Xuanling Shi, Su-Mei Cao, Xinquan Wang*, Mu-Sheng Zeng*, Linqi Zhang*. Nat Commun. 2021 Nov 16;12(1):6624. doi: 10.1038/s41467-021-26912-6.

29. EBV latent membrane proteins promote hybrid epithelial-mesenchymal and extreme mesenchymal states of nasopharyngeal carcinoma cells for tumorigenicity. Nannan Zhu, Xiaoting Xu, Yan Wang, Mu-Sheng Zeng*, Yan Yuan*. PLoS Pathog. 2021 Aug 18;17(8):e1009873. doi: 10.1371/journal.ppat.1009873.  eCollection 2021 Aug.

30. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. Yin-Feng Kang^#, Cong Sun^#, Zhen Zhuang^#, Run-Yu Yuan^#, Qingbing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiao-Hui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nan-Shan Zhong, Yi-Xin Zeng, Guo-Kai Feng*, Changwen Ke*, Jin-Cun Zhao*, Mu-Sheng Zeng*. ACS Nano. 2021 Feb 23;15(2):2738-2752. doi: 10.1021/acsnano.0c08379.  Epub 2021 Jan 19.

31. Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection. Yin-Feng Kang^#, Xiao Zhang^#, Xiao-Hui Yu^#, Qingbing Zheng, Zhe Liu, Jiang-Ping Li, Cong Sun, Xiang-Wei Kong, Qian-Ying Zhu, Hai-Wen Chen, Yang Huang, Miao Xu, Qian Zhong, Yi-Xin Zeng*, Mu-Sheng Zeng*. Nano Lett. 2021 Mar 24;21(6):2476-2486. doi: 10.1021/acs.nanolett.0c04687.  Epub 2021 Mar 8.

32. N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay.Tian-Liang Xia^#, Xingyang Li^#, Xueping Wang^#, Yun-Jia Zhu, Hua Zhang, Weisheng Cheng, Mei-Ling Chen, Ying Ye, Yan Li, Ao Zhang, Dan-Ling Dai, Qian-Ying Zhu, Li Yuan, Jian Zheng, Huilin Huang, Si-Qi Chen, Zhi-Wen Xiao, Hong-Bo Wang, Gaurab Roy, Qian Zhong, Dongxin Lin, Yi-Xin Zeng, Jinkai Wang, Bo Zhao, Benjamin E Gewurz, Jianjun Chen, Zhixiang Zuo*, Mu-Sheng Zeng*. EMBO Rep. 2021 Apr 7;22(4):e50128. doi: 10.15252/embr.202050128.  Epub 2021 Feb 19.

33. CryoEM structure of the tegumented capsid of Epstein-Barr virus. Zhihai Li ^#, Xiao Zhang ^#, Lili Dong, Jingjing Pang, Miao Xu, Qian Zhong, Mu-Sheng Zeng*, Xuekui Yu*. Cell Res. 2020 Oct;30(10):873-884. doi: 10.1038/s41422-020-0363-0.  Epub 2020 Jul 3.

34. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Shi Gao^#, Bing Jia^#, Guokai Feng^#, Chengyan Dong, Hui Du, Lin Bai, Qian Zhong , Qingjie Ma*, Musheng Zeng*, Fan Wang*. Signal Transduct Target Ther. . 2020 Aug 11;5(1):147. doi: 10.1038/s41392-020-00266-9.

35. An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion. Yan Mei^#, Ying-He Li^#, Xiao-Chun Yang^#, Chao Zhou, Zhi-Jian Li, Xiao-Bin Zheng, Jia-Cong Ye, Cheng Li, Xuan-Hong Zhang, Jian-Min Yuan, Hui-Qiang Huang, Wei Fan, Wei-Guang Zhang*, Mu-Sheng Zeng*, Guo-Kai Feng*. Clin Transl Med. 2020 Aug;10(4):e157. doi: 10.1002/ctm2.157.  

36. EphA2 phosphorylates NLRP3 and inhibits inflammasomes in airway epithelial cells. Ao Zhang ^#, Junji Xing ^#, Tianliang Xia ^#, Hua Zhang, Mingli Fang, Shibing Li, Yong Du, Xian C Li , Zhiqiang Zhang*, Mu-Sheng Zeng*. EMBO Rep. 2020 Jul 3;21(7):e49666. doi: 10.15252/embr.201949666.  Epub 2020 Apr 30.

37. Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling. Shi-Bing Li ^#, Yan-Yan Liu ^#, Li Yuan ^#, Ming-Fang Ji ^#, Ao Zhang, Hui-Yu Li, Lin-Quan Tang, Shuo-Gui Fang, Hua Zhang, Shan Xing, Man-Zhi Li, Qian Zhong, Shao-Jun Lin, Wan-Li Liu, Peng Huang, Yi-Xin Zeng, Yu-Ming Zheng, Zhi-Qiang Ling*, Jian-Hua Sui*, Mu-Sheng Zeng*. EMBO Mol Med. 2020 Sep 7;12(9):e12050. doi: 10.15252/emmm.202012050.  Epub 2020 Jul 12.

38. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Xiao Zhang^#, Bingchun Zhao^#, Mingmei Ding, Shuo Song, Yinfeng Kang, Yang Yu, Miao Xu, Tong Xiang, Ling Gao, Qisheng Feng, Qinjian Zhao, * Mu-Sheng Zeng*, Claude Krummenacher, Yi-Xin Zeng*. Theranostics, 2020 Apr 27;10(13):5704-5718. doi: 10.7150/thno.42494.  eCollection 2020.

39. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Ruidong Xue^#, Lu Chen^#, Chong Zhang^#, Masashi Fujita^#, Ruoyan Li, Shu-Mei Yan, Choon Kiat Ong, Xiwen Liao, Qiang Gao, Shota Sasagawa, Yanmeng Li, Jincheng Wang, Hua Guo, Qi-Tao Huang, Qian Zhong, Jing Tan, Lisha Qi, Wenchen Gong, Zhixian Hong, Meng Li, Jingmin Zhao, Tao Peng, Yinying Lu, Kiat Hon Tony Lim, Arnoud Boot, Atushi Ono, Kazuaki Chayama, Zemin Zhang, Steve George Rozen, Bin Tean Teh, Xin Wei Wang, Hidewaki Nakagawa, Mu-Sheng Zeng*, Fan Bai*, Ning Zhang*. Cancer Cell. 2019 Jun 10;35(6):932-947.e8. doi: 10.1016/j.ccell.2019.04.007. Epub 2019 May 23.

40. Room Temperature Detection of Plasma Epstein-Barr Virus DNA with CRISPR-Cas13. Yetao Wu^#, Shang-Xin Liu^#, Fang Wang, Mu-Sheng Zeng. Clin Chem, 2019 Apr;65(4):591-592. doi: 10.1373/clinchem.2018.299347.  Epub 2019 Feb 12.

41. Genome-wide CRISPR-based gene knockout screens reveal cellular factors and pathways essential for nasopharyngeal carcinoma. Chong Wang, Sizun Jiang, Liangru Ke, Luyao Zhang, Difei Li, Jun Liang, Yohei Narita, Isabella Hou, Chen-Hao Chen, Liangwei Wang, Qian Zhong, Yihong Ling, Xing Lv, Yanqun Xiang, Xiang Guo, Mingxiang Teng, Sai-Wah Tsao, Benjamin E Gewurz, Mu-Sheng Zeng*, Bo Zhao*. J Biol Chem, 2019 Jun 21;294(25):9734-9745. doi: 10.1074/jbc.RA119.008793.  Epub 2019 May 9.

42. Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. Guo-Kai Feng^#, Jia-Cong Ye^#, Wei-Guang Zhang^#, Yan Mei, Chao Zhou, Yi-Tai Xiao, Xin-Ling Li, Wei Fan*, Fan Wang*, Mu-Sheng Zeng*. J Control Release, 2019 Sep 28:310:11-21. doi: 10.1016/j.jconrel.2019.08.003.  Epub 2019 Aug 7.

43. The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Qian Zhong ^#, Zhi-Hua Liu ^#, Zhi-Rui Lin ^#, Ze-Dong Hu, Li Yuan, Yan-Min Liu, Ai-Jun Zhou, Li-Hua Xu, Li-Juan Hu, Zi-Feng Wang, Xin-Yuan Guan, Jia-Jie Hao, Vivian W Y Lui, Ling Guo, Hai-Qiang Mai, Ming-Yuan Chen, Fei Han, Yun-Fei Xia , Jennifer R Grandis, Xing Zhang*, Mu-Sheng Zeng*. Clin Cancer Res. 2018 Feb 1;24(3):659-673. doi: 10.1158/1078-0432.CCR-17-0352.  Epub 2017 Nov 13.

44. Identification of a sodium pump Na(+)/K(+) ATPase α1-targeted peptide for PET imaging of breast cancer. Qian Wang ^#, Shi-Bing Li ^#, Yi-Ying Zhao ^#, Da-Nian Dai, Hui Du, Yan-Zhu Lin, Jia-Cong Ye, Jing Zhao, Wei Xiao, Yan Mei, Yi-Tai Xiao, Shi-Chu Liu, Yan Li, Yun-Fei Xia, Er-Wei Song, Gang-Hua Tang, Wei-Guang Zhang, Zhi-Jian Li, Xiao-Bin Zheng, De-Hai Cao, Man-Zhi Li, Qian Zhong, Zhong-Ping Chen, Chao-Nan Qian, Wei Fan*, Guo-Kai Feng*, Mu-Sheng Zeng*. J Control Release, 2018 Jul 10:281:178-188. doi: 10.1016/j.jconrel.2018.05.019.  Epub 2018 May 17.

45. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Xi-Xi Chen^#, Qian Zhong^#, Yang Liu^#, Shu-Mei Yan^#, Zhang-Hua Chen^#, Shan-Zhao Jin^#, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai*, Mu-Sheng Zeng*. Nat Commun, 2017 Sep 12;8(1):524. doi: 10.1038/s41467-017-00650-0.

46. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Junji Xing^#, Ao Zhang^#,  Hua Zhang, Jin Wang, Xian Chang Li*, Mu-Sheng Zeng*, Zhiqiang Zhang*. Nat Commun, 2017 Oct 16;8(1):945. doi: 10.1038/s41467-017-00101-w.  

47. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. Lin-Quan Tang^#, Chao-Feng Li^#, Jing Li^#, Wen-Hui Chen^#, Qiu-Yan Chen, Lian-Xiong Yuan, Xiao-Ping Lai, Yun He, Yun-Xiu-Xiu Xu, Dong-Peng Hu, Shi-Hua Wen, Yu-Tuan Peng, Lu Zhang, Shan-Shan Guo, Li-Ting Liu, Ling Guo, Yi-Shan Wu, Dong-Hua Luo, Pei-Yu Huang, Hao-Yuan Mo, Yan-Qun Xiang, Rui Sun, Ming-Yuan Chen, Yi-Jun Hua, Xing Lv, Lin Wang, Chong Zhao, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Yi-Xin Zeng*, Hai-Qiang Mai*, Mu-Sheng Zeng*. J Natl Cancer Inst, 2015 Oct 14;108(1):djv291. doi: 10.1093/jnci/djv291. 

48. In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Chao Ni^#, Yuhui Chen^#, Musheng Zeng^#, Rongjuan Pei, Yong Du, Linquan Tang, Mengyi Wang, Yazhuo Hu, Hanyu Zhu, Meifang He, Xiawei Wei, Shan Wang, Xiangkai Ning, Manna Wang, Jufang Wang, Li Ma, Xinwen Chen, Qiang Sun, Hong Tang, Ying Wang*, Xiaoning Wang*. Cell Res, 2015 Jul;25(7):785-800. doi: 10.1038/cr.2015.50.  Epub 2015 Apr 28.

49. SPECT and near-infrared fluorescence imaging of breast cancer with a  neuropilin-1-targeting peptide. Guo-Kai Feng^#, Rong-Bin Liu^#, Meng-Qing Zhang^#, Xiao-Xuan Ye, Qian Zhong, Yun-Fei Xia, Man-Zhi Li, Jun Wang, Er-Wei Song, Xing Zhang*, Zhao-Zhong Wu*, Mu-Sheng Zeng*. J Control Release, 2014 Oct 28:192:236-42. doi: 10.1016/j.jconrel.2014.07.039.  Epub 2014 Jul 22.

50. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Li Yuan^#, Zhi-Hua Liu^#, Zhi-Rui Lin, Li-Hua Xu, Qian Zhong*, Mu-Sheng Zeng*. Cancer Biol Ther, 2014;15(12):1613-21. doi: 10.4161/15384047.2014.961874.

51. Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. Jing-Ping Zhang^#, Hua Zhang^#, Hong-Bo Wang^#, Yan-Xian Li, Gui-Hong Liu, Shan Xing, Man-Zhi Li, Mu-Sheng Zeng. J Transl Med, 2014 Aug 7:12:222. doi: 10.1186/s12967-014-0222-1.  

52. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose  positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial  staging. Lin-Quan Tang^#, Qiu-Yan Chen^#, Wei Fan^#, Huai Liu^#, Lu Zhang, Ling Guo, Dong-Hua Luo, Pei-Yu Huang, Xu Zhang, Xiao-Ping Lin, Yun-Xian Mo, Li-Zhi Liu, Hao-Yuan Mo, Jian Li, Ru-Hai Zou, Yun Cao, Yan-Qun Xiang, Fang Qiu, Rui Sun, Ming-Yuan Chen, Yi-Jun Hua, Xing Lv, Lin Wang, Chong Zhao, Xiang Guo, Ka-Jia Cao, Chao-Nan Qian, Mu-Sheng Zeng, Hai-Qiang Mai. J Clin Oncol, 2013 Aug 10;31(23):2861-9. doi: 10.1200/JCO.2012.46.0816.  Epub 2013 Jul 15.

53. Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. Hong-Bo Wang^#, Gui-Hong Liu^#, Hua Zhang, Shan Xing, Li-Juan Hu, Wei-Feng Zhao, Bo Xie, Man-Zhi Li, Bo-Hang Zeng, Yingqiu Li, Mu-Sheng Zeng. FEBS J, 2013 Jun;280(12):2929-44. doi: 10.1111/febs.12299.  Epub 2013 May 24.

54. Anti-tumour activity of longikaurin A (LK-A), a novel natural diterpenoid, in nasopharyngeal carcinoma. Qing-Feng Zou^#, Ji-Ke Du^#, Hua Zhang, Hong-Bo Wang, Ze-Dong Hu, Shu-Peng Chen, Yong Du, Man-Zhi Li, Dan Xie, Juan Zou, Han-Dong Sun, Jian-Xin Pu*, Mu-Sheng Zeng*. J Transl Med, 2013 Aug 28:11:200. doi: 10.1186/1479-5876-11-200.  

55. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. Feng-Hua Xu^#, Dan Xiong^#, Ya-Fei Xu^#, Su-Mei Cao, Wen-Qiong Xue, Hai-De Qin, Wen-Sheng Liu, Jing-Yan Cao, Ying Zhang, Qi-Sheng Feng, Li-Zhen Chen, Man-Zhi Li, Zhi-Wei Liu, Qing Liu, Ming-Huang Hong, Yin Yao Shugart, Yi-Xin Zeng, Mu-Sheng Zeng*, Wei-Hua Jia*. J Natl Cancer Inst, 2 2012 Sep 19;104(18):1396-410. doi: 10.1093/jnci/djs320.  Epub 2012 Sep 12.

56. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Bao-Hong Guo^#, Yan Feng^#, Rong Zhang, Li-Hua Xu, Man-Zhi Li, Hsiang-Fu Kung, Li-Bing Song, Mu-Sheng Zeng*. Mol Cancer, 2011 Jan 28;10(1):10. doi: 10.1186/1476-4598-10-10.

57. Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. B-H Guo, X Zhang, H-Z Zhang, H-L Lin, Y Feng, J-Y Shao, W-L Huang, H-F Kung, M-S Zeng. Ann Oncol, 2010 Dec;21(12):2361-2369. doi: 10.1093/annonc/mdq241. 

58. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. Qing-Li Kong^#, Li-Juan Hu^#, Jing-Yan Cao^#, Yi-Jun Huang, Li-Hua Xu, Yi Liang, Dan Xiong, Su Guan, Bao-Hong Guo, Hai-Qiang Mai, Qiu-Yan Chen, Xing Zhang, Man-Zhi Li, Jian-Yong Shao, Chao-Nan Qian, Yun-Fei Xia, Li-Bing Song, Yi-Xin Zeng, Mu-Sheng Zeng*. PLoS Pathog, 2010 Jun 3;6(6):e1000940. doi: 10.1371/journal.ppat.1000940.  

59. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Jing-Yan Cao^#, Li Liu^#, Shu-Peng Chen, Xing Zhang, Yan-Jun Mi, Zhi-Gang Liu, Man-Zhi Li, Hua Zhang, Chao-Nan Qian, Jian-Yong Shao, Li-Wu Fu, Yun-Fei Xia*, Mu-Sheng Zeng*. Mol Cancer, 2010 Sep 9:9:237. doi: 10.1186/1476-4598-9-237.

60. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Wen-Ting Liao^#, Li-Bing Song^#, Hui-Zhong Zhang, Xing Zhang, Ling Zhang, Wan-Li Liu, Yan Feng, Bao-Hong Guo, Hai-Qiang Mai, Su-Mei Cao, Man-Zhi Li, Hai-De Qin, Yi-Xin Zeng, Mu-Sheng Zeng*. Clin Cancer Res, 2007 Jan 15;13(2 Pt 1):508-14. doi: 10.1158/1078-0432.CCR-06-1512.  

61. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Li-Bing Song, Mu-Sheng Zeng*, Wen-Ting Liao, Ling Zhang, Hao-Yuan Mo, Wan-Li Liu, Jian-Yong Shao, Qiu-Liang Wu, Man-Zhi Li, Yun-Fei Xia, Li-Wu Fu, Wen-Lin Huang, Goberdhan P Dimri, Vimla Band, Yi-Xin Zeng. Cancer Res, 2006 Jun 15;66(12):6225-32. doi: 10.1158/0008-5472.CAN-06-0094.

62. A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. J Ri-Cheng Jiang^#, Hai-De Qin^#, Mu-Sheng Zeng^#, Wei Huang, Bing-Jian Feng, Feng Zhang, Han-Kui Chen, Wei-Hua Jia, Li-Zhen Chen, Qi-Sheng Feng, Ru-Hua Zhang, Xing-Juan Yu, Mei-Zhen Zheng, Yi-Xin Zeng. Cancer Res, 2 2006 Jan 15;66(2):693-700. doi: 10.1158/0008-5472.CAN-05-2166.

63. The human kallikrein 10 promoter contains a functional retinoid response element. Musheng Zeng, Ying Zhang, Ishfaq Bhat, David E Wazer, Hamid Band, Vimla Band. Biol Chem, 2006 Jun;387(6):741-7. doi: 10.1515/BC.2006.093.

64. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. Mu-Sheng Zeng, Da-Jiang Li, Qing-Lun Liu, Li-Bing Song, Man-Zhi Li, Ru-Hua Zhang, Xing-Juan Yu, Hui-Min Wang, Ingemar Ernberg, Yi-Xin Zeng. J Virol, 2005 Dec;79(24):15323-30. doi: 10.1128/JVI.79.24.15323-15330.2005.

65. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. Musheng Zeng, Ajay Kumar, Gaoyuan Meng, Qingshen Gao, Goberdhan Dimri, David Wazer, Hamid Band, Vimla Band. J Biol Chem, 2002 Nov 22;277(47):45611-8. doi: 10.1074/jbc.M208447200.  Epub 2002 Sep 15.